Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sanjeet Sandhu

Pediatric Endocrinology El Paso, TX Doctor of Osteopathy

NPI 1336568708 CMS profile 4216828

12220 Rc Poe Rd Ste A, Apt 1265, El Paso, TX 79938

Open in the dashboard

General payments

$4,534

202 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjeet Sandhu of El Paso, TX is reported in the CMS Open Payments database as having received $4,534 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $607 30
2024 General $618 34
2023 General $879 40
2022 General $1,306 50
2021 General $883 36
2020 General $240 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjeet Sandhu
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Sanjeet Sandhu were reported at $607. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Sanjeet Sandhu Pediatric Endocrinology median Middle half National median
2019 $0 $196 $68–$845 $163
2020 $240 $124 $37–$722 $114
2021 $883 $134 $35–$691 $132
2022 $1,306 $177 $47–$726 $149
2023 $879 $236 $75–$887 $160
2024 $618 $259 $91–$979 $164
2025 $607 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Insulet Corporation $879 37 payments
  2. AbbVie, Inc. $784 39 payments
  3. Abbott Laboratories $641 26 payments
  4. Ascendis Pharma, Inc. $586 19 payments
  5. Tolmar, Inc. $308 12 payments
  6. Dexcom, Inc. $301 13 payments
  7. TOLMAR Pharmaceuticals, Inc. $182 10 payments
  8. Novo Nordisk Inc $106 5 payments
  9. CutisPharma, Inc. $105 6 payments
  10. Pfizer Inc. $92 5 payments
  11. Other $550 30 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,534 202 payments
Products named General payments · program years 2020–2025
  1. Omnipod $879 37 payments
  2. LUPRON DEPOT $749 37 payments
  3. SKYTROFA $586 19 payments
  4. FENSOLVI $406 17 payments
  5. FreeStyle Libre 2 $249 7 payments
  6. FreeStyle Libre 3 $246 15 payments
  7. DEXCOM G6 TRANSMITTER Endocrinology $173 6 payments
  8. FREESTYLE LIBRE $130 3 payments
  9. Dexcom G6 Transmitter Endocrinology $105 6 payments
  10. Triptodur $98 6 payments
  11. Other $827 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record